Skip to main content
PEPTIDE / PORTAL
OverviewVendorsScienceReference
Exenatide product
Metabolic Pathway Research ·

ExenatideByetta; Bydureon; Exendin-4

GLP-1 receptor agonist research

Also known as Byetta; Bydureon; Exendin-4.

6 papers·FDA-approved·COA Unverified·0 saved
Scientific name
Byetta; Bydureon; Exendin-4
Category
Metabolic Pathway Research
US status
Research only

Evidence last verified May 9, 2026

0 results
No vendor products match the selected size.

Scientific Details

Scientific Research
YearTitle / JournalTypeCites
2025
Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study
European Journal of Endocrinology
Clinical Trial0
2025
Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes
Cardiovascular Diabetology
Clinical Trial0
2025
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Annals of Neurology
Clinical Trial0
2025
Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder
Alcohol, Clinical & Experimental Research
Clinical Trial0
2025
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes
Diabetes Care
Clinical Trial0
2017
Holman 2017 — EXSCEL Exenatide Cardiovascular Outcomes
New England Journal of Medicine
RCT2900

Showing 6 of 6 papers

Reference

Regulatory Status
USResearch only
EUNot approved
UKResearch only
AUResearch only

Regulatory status may change. Always verify current regulations in your jurisdiction before purchase.